Vanguard Global Advisers’s MacroGenics MGNX Stock Holding History

Vanguard Global Advisers’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105K	Hold	22,820	–	–	﹤0.01%	2756
2026 Q1	$66K	Buy	+22,820	New	+$48.7K	﹤0.01%	2896

Other funds holding MGNX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Global Advisers's MGNX Position: Q2 2026 in Review

Vanguard Global Advisers held its MacroGenics (MGNX) position steady in Q2 2026 at 22,820 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #2756.

Vanguard Global Advisers first reported a position in MGNX in Q1 2026 and has held it in 2 quarters since. 121 funds tracked by Wall St. Rank hold MGNX as of Q2 2026.

Vanguard Global Advisers held 22,820 shares of MacroGenics worth $105K as of Q2 2026.
Vanguard Global Advisers left its MacroGenics share count unchanged in Q2 2026.
MacroGenics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2756 holding.
Vanguard Global Advisers first reported a position in MacroGenics in Q1 2026 and has held it in 2 quarters since.
121 funds tracked by Wall St. Rank held MacroGenics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.